Bridging local-global transmembrane protein contexts with contrastive pretraining for alignment-free pathogenicity prediction.

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: Up to 0.93 accuracy reported; consistent outperformance of leading existing predictors across benchmarks (magnitude of improvement not quantified in abstract)

• Primary Outcome: Classification of transmembrane protein variants as pathogenic or benign across diverse TMP benchmarks under protein-level group splits

• Nnt Or Sensitivity: Sensitivity, specificity, and AUC not reported in abstract; accuracy alone is insufficient for clinical triage assessment

• Confidence Interval: Not reported

Clinical Application

The alignment-free, computationally efficient design is a genuine practical advantage for clinical genomics laboratories lacking access to large multiple sequence alignment pipelines. However, the tool is explicitly positioned for research use only and would require prospective clinical validation, regulatory evaluation, and integration into variant interpretation workflows (e.g., ACMG/AMP criteria) before clinical deployment. No software availability, licensing, or implementation details are provided in the abstract. Transmembrane protein variants are clinically relevant across multiple Australian specialist services including cardiac genetics (KCNQ1, SCN5A channelopathies), neurogenetics, and rare disease genomics programs. Australian clinical genomics laboratories operate under NPAAC and RCPA guidelines for variant classification, and any computational tool would need to demonstrate concordance with ACMG/AMP variant classification standards. The tool is not TGA-regulated as a medical device in its current research form. Medicare Benefits Schedule (MBS) items for genomic testing (e.g., MBS 73358, 73360) increasingly drive demand for scalable variant interpretation tools, making alignment-free approaches potentially valuable for the Australian Genomics Health Alliance and state-based genomics programs. PBS-listed treatments for channelopathies (e.g., beta-blockers for long QT syndrome) could benefit from improved variant triage, but clinical deployment would require RACGP and RACP endorsement and prospective validation in Australian cohorts. Patients undergoing clinical genomic sequencing where transmembrane protein variants of uncertain significance are identified, particularly in channelopathies (e.g., KCNQ1-related long QT syndrome), inherited cardiac conditions, neurological disorders, and other TMP-associated Mendelian diseases

Abstract

Predicting the pathogenic consequences of protein mutations is a cornerstone of precision medicine, yet it remains a formidable challenge for transmembrane proteins (TMPs), a clinically vital class of drug targets. Existing computational methods are often hampered by their reliance on evolutionary data and fail to model TMP-specific biophysical constraints. Here, we introduce Memo-Patho, a deep learning framework for robust, alignment-free pathogenicity prediction of TMP variants. The core innovation is a within-protein, label-informed supervised contrastive pretraining strategy that learns sequence-encoded biophysical signatures distinguishing pathogenic and benign variants by directly comparing them within the same protein context. By fusing sequence-level representations from protein language models with local structural proxies derived from sequence, Memo-Patho achieves accurate predictions without multiple sequence alignments or experimental structures. Across diverse TMP benchmarks and under protein-level group splits, Memo-Patho consistently outperforms leading predictors, achieving up to 0.93 accuracy, and it transfers to an independent KCNQ1 ion-channel cohort without re-training. Its resource-efficient, alignment-free design enables routine large-scale screening when evolutionary or structural data are sparse. Conceptually, Memo-Patho addresses a key gap by directly learning discriminative, sequence-anchored signatures pertinent to TMP-specific constraints, offering a principled and generalizable foundation for research-use clinical variant triage and proteome-wide mutation-effect modeling.

References

1. 1.Bao, Y., Liu, Z., Zhao, F., Li, W., Jin, H., & Lin, G. N. (2026). Bridging local-global transmembrane protein contexts with contrastive pretraining for alignment-free pathogenicity prediction. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbag352